Literature DB >> 14576555

Efficacy, safety, and pharmacokinetics of levobupivacaine with and without fentanyl after continuous epidural infusion in children: a multicenter trial.

Jerrold Lerman1, Judith Nolan, Rob Eyres, Mark Schily, Peter Stoddart, Christopher M Bolton, Frank Mazzeo, Andrew R Wolf.   

Abstract

BACKGROUND: Levobupivacaine, the levo-enantiomer of bupivacaine, is as potent as bupivacaine but less toxic. Therefore, the authors investigated the efficacy, safety, and pharmacokinetics of perioperative epidural levobupivacaine with and without fentanyl in children.
METHODS: After Research Ethics Board approval and informed written consent, 120 healthy children aged 6 months to 12 yr who were scheduled to undergo urologic or abdominal surgery were randomized in a double-blinded and concealed manner to receive one of four epidural solutions as a continuous infusion for 24 h: 0.125% levobupivacaine; 0.0625% levobupivacaine; 1 mug/ml fentanyl; or the combination, 0.0625 levobupivacaine and 1 mug/ml fentanyl. After induction of anesthesia and tracheal intubation, a lumbar epidural catheter was sited, a loading dose was administered (0.75 ml/kg levobupivacaine, 0.175%), and the epidural infusion was commenced. The primary endpoint was the need for rescue analgesia (morphine) in the first 10 h after surgery. Pain, motor strength, and side effects were recorded for 24 h. Venous blood was collected from 18 children to determine the plasma concentrations of levobupivacaine and/or fentanyl before and 2, 4, 8, 16, 24, and 26 or 30 h after the start of the epidural infusion.
RESULTS: Of the 114 children who were analyzed for intention to treat, a similar number of children in each group reached the 10-h mark. The time to the first dose of morphine in the first 10 h was less in the plain fentanyl group (P < 0.044). All other effects were similar among the four groups. The plasma concentration of levobupivacaine increased during the infusion period, reaching a maximum of 0.76 +/- 0.11 mug/ml in the 0.125% group and 0.48 +/- 0.12 mug/ml in the 0.0625% group by 24 h. The plasma concentration of fentanyl also increased steadily, reaching a maximum concentration of 0.37 +/- 0.11 ng/ml by 24 h.
CONCLUSION: We conclude that 0.0625% levobupivacaine without fentanyl is an effective perioperative epidural solution in children when infused at a rate of 0.3 ml. kg-1. h-1. The plasma concentrations of 0.125% and 0.0625% levobupivacaine and fentanyl (1 mug/ml) at the end of a 24-h infusion are low.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576555     DOI: 10.1097/00000542-200311000-00025

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  5 in total

Review 1.  [Levobupivacaine for regional anesthesia. A systematic review].

Authors:  B Urbanek; S Kapral
Journal:  Anaesthesist       Date:  2006-03       Impact factor: 1.041

Review 2.  Local anesthetic systemic toxicity (LAST) - Should we not be concerned?

Authors:  Rakhee Goyal; R N Shukla
Journal:  Med J Armed Forces India       Date:  2012-07-17

3.  Evaluation of spinal toxicity and long-term spinal reflex function after intrathecal levobupivaciane in the neonatal rat.

Authors:  Emre Hamurtekin; Bethany L Fitzsimmons; Veronica I Shubayev; Marjorie R Grafe; Ronald Deumens; Tony L Yaksh; Suellen M Walker
Journal:  Anesthesiology       Date:  2013-07       Impact factor: 7.892

4.  A moldable sustained release bupivacaine formulation for tailored treatment of postoperative dental pain.

Authors:  Sarah D Shepherd; Sandra C O'Buckley; James M Harrington; Laura G Haines; Ginger D Rothrock; Leah M Johnson; Andrea G Nackley
Journal:  Sci Rep       Date:  2018-08-15       Impact factor: 4.379

5.  Analgesic effect of ropivacaine with fentanyl in comparison with ropivacaine alone for continuous femoral nerve block after knee replacement arthroplasty: a prospective, randomized, double-blinded study.

Authors:  Gunn Hee Kim; Joon Woo Lee; Go Eun Kim; Seong Su Lee; Shill Lee Son; Byung Uk Kim; Ha Na Cho; Mi Young Kwon; Min Seok Koo; Ji Eun Kim; Mi Jung Yun
Journal:  Anesth Pain Med (Seoul)       Date:  2020-04-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.